A group of researchers, led by CSI Singapore’s Prof. Lee Soo Chin, evaluated the clinical outcomes for combinations of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) with anti-oestrogen therapy for treatment of advanced stage or metastatic oestrogen receptor positive, human epidermal growth factor receptor-2 (HER2) negative breast cancer (BC), the most frequently diagnosed BC subtype. Their findings facilitate treatment planning, insights into the incidence of drug toxicities, dose modifications – including dose delays (DDs) and dose reductions (DRs), and improves prognostic accuracy in subgroups, for example geriatric patients, who are under-represented in clinical trials.

Read more at: http://shorturl.at/aoALW